Tag - NRXP

Executive Moves

Prof. Joshua C. Brown joins NRx as CMO

NRx Pharmaceuticals (NASDAQ: NRXP) has announced the appointment of Prof. Joshua C. Brown, MD, PhD, as chief medical officer. Prof. Brown, a pioneer in understanding the biologic effect of Transcranial Magnetic...

March 2, 2026

Developments

NRx’s NRC-100 receives Fast Track Designation for suicide ideation in depression

NRx Pharmaceuticals (NASDAQ: NRXP) has announced that the FDA has granted NRC-100 Fast Track Designation as a standalone drug for the treatment of suicidal ideation in patients with depression, including bipolar...

August 11, 2025

Developments

NRx Pharmaceuticals submits IND for chronic pain

NRx Pharmaceuticals (NASDAQ:NRXP) submitted an investigational new drug (IND) application to the FDA for the use of NRX-101 to treat chronic pain. The IND application leverages pioneering research on the use of D...

August 30, 2023

Markets

Dawson James ups NRx Pharma PT to $9 from $3

Dawson James Securities raised its price target for NRx Pharmaceuticals (NASDAQ:NRXP) to $9 from $3, saying the company’s NRX-101 drug candidate could change the treatment paradigm for depression, PTSD, and related...

April 3, 2023

Markets

Dawson James starts NRx Pharma at buy; PT $3.00

Dawson James Securities initiated coverage of NRx Pharmaceuticals (NASDAQ:NRXP) with a “buy” rating and $3.00 price target. The stock closed at 68 cents on March 16. NRx Pharmaceuticals is a clinical-stage...

March 17, 2023